Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
about
Clinical and economic studies of eptifibatide in coronary stentingRoutine early versus deferred provisional tirofiban treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Glycoprotein IIb/IIIa inhibitors use and outcome after percutaneous coronary intervention for non-ST elevation myocardial infarction.Measuring hospital performance in the management of acute coronary syndromes.Comparison of documentation and evidence-based medicine use for non-ST-segment elevation myocardial infarction among cardiology, teaching, and nonteaching teams.Newer agents in antiplatelet therapy: a review.The 2012 ACCF/AHA Focused Update of the Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Guideline: a critical appraisalAntiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerationsIntracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience.2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies.Heparin Versus Bivalirudin in Acute Myocardial Infarction: Unfractionated Heparin Monotherapy Elevated to Primary Treatment in Contemporary Percutaneous Coronary Intervention.Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).Benefit of standard versus low-dose tirofiban for percutaneous coronary intervention in very elderly patients with high-risk acute coronary syndrome.Clinical applications of bivalirudin in the cardiac catheterization laboratory.Acute coronary syndromes: from the emergency department to the catheterization laboratory-integrating evidence from recent ACS/NSTEMI trials into clinical practice: an evidence-based review of recent clinical trial results and report on a roundtableThe evolution of antiplatelet therapy in cardiovascular disease.Anti-platelet therapy: glycoprotein IIb-IIIa antagonistsOptimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions.2011 ACCF/AHA focused update of the guidelines for the management of patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 Guideline): highlights for the clinician.Unstable angina and non-ST elevation myocardial infarction.Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes.Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice.The platelet fibrinogen receptor: from megakaryocyte to the mortuary.Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease.Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX).Antiplatelet therapy in acute coronary syndromes.Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of EP2Y12 Inhibitor Pre-Treatment in Non-ST-Elevation Acute Coronary Syndrome: A Decision-Analytic Model.Abciximab: a reappraisal of its use in coronary care.Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Association of Interventional Cardiology (SICI-GISE) and Italian Society of Cardiac Surgery (SICCH): clinical approach to pImpact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial.Glycoprotein IIb-IIIa inhibitors - do we still need them?Antithrombotic Therapy for ACS in Elderly Patients.
P2860
Q26830199-CFF64DF7-879F-422D-86BF-E9755E32C70AQ33406801-06E1EDDD-FB24-40AA-83B0-09E5DCEAF296Q33666662-572FF097-4395-4E27-88F2-35AF889724D1Q33906076-CF95E3BA-7A45-4C4A-BA51-E64EA2C05247Q35712074-1930E6AD-C127-4869-B880-4708B80085F2Q36085620-57379F9A-2646-4ED8-9874-9A49CBA7CC97Q36367018-E07D1797-5C0C-4539-98A9-F4BDD490CE65Q36754513-B1C00B2C-15FB-432A-8CDE-08238792D674Q37138914-2BB3D44F-2985-450F-80B9-07FDBF9FC935Q37199530-479FC381-847C-4CCB-A0E3-7612189607C6Q37212502-82434D36-FAA0-452C-B05D-26DBCE910DF6Q37221845-DCEAA1FB-0061-4FC7-8403-4119B53F3B5CQ37728945-E9AA6984-D423-4424-A5C2-7B9A60171CABQ37811622-1D80CCC9-32FE-40A7-ADED-24ADA7651679Q37813151-8B05303E-34DF-48BC-8CBA-964E78ADA4F6Q37900470-00205333-2A9A-4032-9F10-95B9B6865306Q37929839-8E2C112F-6D9A-4E57-A592-4421F7A78163Q37943829-4A421F72-547A-462C-B36C-73E3788C6191Q37965481-D74BC997-E078-4293-BBE6-DCC2BA318408Q37972109-707B2597-D42B-463B-B488-3D686F43171FQ38079917-241A61C4-12AE-48DF-9546-EFE4238AC9AFQ38118745-5A36EBEA-2740-41C5-BD16-C5C7C4386BD6Q38156780-786220B1-528C-40A7-8118-152D1DF3CCF0Q38182003-B6B4C766-5641-46C4-9088-8DB6DFF2575AQ38216215-68BC6A70-935C-45EC-8D40-9015A2F6AA27Q38570608-DD7547B8-3D0C-4F60-9318-3B689D58F464Q38656364-34CCCE72-BCC6-4C62-AD9F-EE4731A70657Q39466995-84DE3B95-D863-4D31-81DF-20D05B18794EQ40119259-3E99E5C7-F7DC-49C7-BDFB-28160BDBAD3AQ41082977-E90E1101-2745-40E0-A7BE-7156ACEC1418Q41430853-FD08E9B8-C9DE-49FA-8C94-45659B0807CBQ42804088-3AAB69E3-3ADB-49F7-A1CB-11644AAAD128Q47632915-C252F5CC-D50F-4985-B7F2-8D94C4E927ED
P2860
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Routine upstream initiation vs ...... omes: the ACUITY Timing trial.
@en
type
label
Routine upstream initiation vs ...... omes: the ACUITY Timing trial.
@en
prefLabel
Routine upstream initiation vs ...... omes: the ACUITY Timing trial.
@en
P2093
P50
P356
P1476
Routine upstream initiation vs ...... omes: the ACUITY Timing trial.
@en
P2093
ACUITY Investigators
Brent T McLaurin
David A Cox
David J Cohen
Franz Hartmann
Franz Leisch
Gregg W Stone
Harish Chandna
Harvey D White
Ira H Lieber
P304
P356
10.1001/JAMA.297.6.591
P407
P577
2007-02-01T00:00:00Z